J.P. Morgan analyst Jessica Fye has maintained their bullish stance on SRRK stock, giving a Buy rating on August 7.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jessica Fye’s rating is based on the promising potential of Scholar Rock Holding’s innovative therapies, particularly in the treatment of spinal muscular atrophy (SMA). The company’s focus on developing novel approaches to address unmet medical needs positions it well within the competitive biotechnology landscape.
Additionally, Scholar Rock’s strategic advancements and clinical progress in its pipeline have been noteworthy, providing a strong foundation for future growth. The company’s ability to leverage its scientific expertise to drive innovation further supports the positive outlook. These factors combined contribute to the Buy rating, reflecting confidence in Scholar Rock’s capacity to deliver value to investors.
In another report released on August 7, BMO Capital also maintained a Buy rating on the stock with a $45.00 price target.